Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma

Molecular Pharmacology

Volumn 64, Issue 2, 2003, Pages 415-420

  Drucker, Liat ^a   Uziel, Orit ^a   Tohami, Tali ^a   Shapiro, Hava ^a   Radnay, Judith ^a   Yarkoni, Shai ^a   Lahav, Meir ^a,b   Lishner, Michael ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD63 ANTIGEN; GREEN FLUORESCENT PROTEIN; SOMATOMEDIN C RECEPTOR; TELOMERASE; THALIDOMIDE; TRANSCRIPTION FACTOR SP1;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; DRUG TARGETING; ENZYME ACTIVITY; GC RICH SEQUENCE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; RACEMIC MIXTURE; REPORTER GENE; STEREOCHEMISTRY; TERATOGENICITY; TRANSCRIPTION REGULATION;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANTIGENS, CD; ANTIGENS, CD29; DNA-BINDING PROTEINS; GC RICH SEQUENCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; PLASMACYTOMA; PLATELET MEMBRANE GLYCOPROTEINS; PROMOTER REGIONS (GENETICS); RECEPTORS, SOMATOMEDIN; RNA, MESSENGER; TELOMERASE; THALIDOMIDE; TUMOR CELLS, CULTURED;

EID: 0041842545     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.2.415     Document Type: Article

References (35)

1. Cooke DW, Bankert LA, Roberts CT Jr, LeRoith D and Casella SJ (1991) Analysis of the human type I insulin-like growth factor receptor promoter region. Biochem Biophys Res Commun 177:1113-1120.
2. D'Amato RJ, Lentzsch S, Anderson KC, and Rogers MS (2001) Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 28:597-601.
3. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, and Lassota P (1992) Features of apoptotic cells measured by flow cytometry. Cytometry 13:795-808.
4. Epstein J and Yaccoby S (2002) Interactions between the bone marrow stroma and myeloma. Hematol J 2 Suppl:45-47.
5. Erikkson T, Bjorkman S, and Hoglund P (2001) Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 57:365-376.
6. Ge NL and Rudikoff S (2000) Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 96:2856-2861.
7. Hahn WC, Counter CM, Lundberg AS, Bijeersbergen RL, brooks MW and Weinberg RA (1999) Creation of human tumor cells with defined genetic elements. Nature (Lond) 400:464-468.
8. Heney D, Norfolk DR, Wheeldon J, Bailey CC, Lewis IJ, and Barnard DL (1991) Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 78:23-27.
9. Hotta H, Miyamoto H, Hara I, Takahashi N, and Homma M (1992) Genomic structure of the ME491/CD63 antigen gene and functional analysis of the 5′-flanking regulatory sequences. Biochem Biophys Res Commun 185:436-442.
10. Jaiswal AS and Narayan S (2001) P53 dependent transcriptional regulation of the APC promoter in colon cancer cells treated with DNA alkylating agents. J Biol Chem 276:18193-18199.
11. Kenneth SB, Dixon SC, and Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834.
12. Maecker HT, Todd SC, and Levy S (1997) The tetraspanin superfamily: molecular facilitators. FASEB J 11:428-442.
13. Marks MG, Shi J, Fry MO, Xiao Z, Trzyna M, Pokala V, Ihnat MA, and Li PK (2002) Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol Pharm Bull 25:597-604.
14. Mujagic H, chabner BA and Mujagic Z (2002) Mechanisms of action and potential therapeutic uses of thalidomide. Croat Med J 43:274-285.
15. Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho AD, and Goldschmidt H (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 115:605-608.
16. Ng SSW, Brown M, and Figg WD (2002) Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomed Pharmacother 56:194-199.
17. Nightingale SL (1998) From the food and drug administration. J Am Med Assoc 280:872.
18. Nilsson K, Georgii-Hemming P, Spets H, and Jemberg-Wiklund H (1999) The control of proliferation, survival and apoptosis in human myeloma cells in vitro. Curr Top Microbiol Immunol 246:325-332.
19. Nilsson P, Mehle C, Remes K, and Roos G (1994) Telomerase activity in vivo in human malignant hematopoietic cells. Oncogene 9:3034-3038.
20. Nomura S, Kagawa H, Ozaki Y, Nagahama M, Yoshimura C and Fukuhara S (1999) Relationship between platelet activation and cytokines in systemic inflammartory response syndrome patients with hematological malignancies. Thromb Res 95:205-213.
21. Noopur R (1999) Thalidomide- a revival story. N Engl J Med 341:1606-1609.
22. Physicians' Desk Reference (2000) 54th ed. Medical Economics Company, Montvale, NJ. Thalidomide, p. 3457-3462.
23. Qiang YW, Kopantzev E and Rudukoff S (2002) Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates and pathway cross-talk. Blood 99:4138-4146.
24. Rajkumar SV (2001) Thalidomide in the treatment of multiple myeloma. Expert Rev Anticancer Ther 1:20-28.
25. Richardson P, Hideshima T, and Anderson K (2002) Thalidomide in multiple myeloma. Biomed Pharmacother 56:115-128.
26. Shiratsuchi M, Muta K, Umemura T, Nishimura J, Nawata H, and Kozuru M (1999) Telomerase activity in myeloma cells is closely related to cell cycle status, but not to apoptotic signals induced by interferon-alpha. Leuk Lymphoma 34:349-359.
27. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, et al. (1999) Anti tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571.
28. Singhal S, Tricot G, and Jagannath S (1998) Outcome of relapse after transplantation in myeloma (Abstract). Blood 88 Suppl 1:611a.
29. Stephens TD and Fillmore BJ (2000) Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology 61:189-195.
30. Stephens TD, Bunde CJ, and Fillmore BJ (2000) Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59:1489-1499.
31. Stephens TD, Bunde CJW, Torres RD, Hackett DA, Stark MR, Smith DM, and Fillmore BJ (1998) Thalidomide inhibits limb development through its antagonism of IGF-I + FGF-2 + heparin (Abstract). Teratology 57:112.
32. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, and Inoue M (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59:551-557.
33. Thomas D and Kantarjian H (2001) The revitalization of thalidomide. Ann Oncol 12:885-886.
34. Urquidi V, Tarin D, and Goodstein S (2000) Role of telomerase in cell senescence and oncogenesis. Ann Rev Med 51:65-79.
35. Villa-Garcia M, Li L, Riely G, and Bray PF (1994) Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene. Blood 83:668-676.